Relative Bioavailability of Both BI 10773 and Warfarin and Pharmacodynamics of Warfarin After Co-administration Compared to Multiple Oral Doses of BI 10773 (25 mg Once Daily) and a Single Oral Dose of Warfarin (25mg) Alone in Healthy Male Volunteers (an Open-label,Crossover, Clinical Phase I Study).

Trial Profile

Relative Bioavailability of Both BI 10773 and Warfarin and Pharmacodynamics of Warfarin After Co-administration Compared to Multiple Oral Doses of BI 10773 (25 mg Once Daily) and a Single Oral Dose of Warfarin (25mg) Alone in Healthy Male Volunteers (an Open-label,Crossover, Clinical Phase I Study).

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2014

At a glance

  • Drugs Empagliflozin; Warfarin
  • Indications Thrombosis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 15 Jul 2010 Actual end date added to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 15 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top